Regencell Bioscience Holdings Ltd
- CIK: 0001829667
- EIN: 00-0000000
- Business address: 11/F FIRST COMMERCIAL BUILDING, 33-35 LEIGHTON ROAD, CAUSEWAY BAY, HONG KONG, Hong Kong, 999077
Information
Mailing address
11/F FIRST COMMERCIAL BUILDING, 33-35 LEIGHTON ROAD, CAUSEWAY BAY, HONG KONG, Cayman Islands, 999077Phone
852 2155 0823State location
Hong KongState of incorporation
Cayman IslandsFiscal year end
N/ASIC
2833 - (CF Office: Office of Life Sciences) MEDICINAL CHEMICALS & BOTANICAL PRODUCTSFilings
N/A
About Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Ltd (CIK: 0001829667) is an American company incorporated in the state of Hong Kong. Head office is located at 11/F FIRST COMMERCIAL BUILDING, 33-35 LEIGHTON ROAD, CAUSEWAY BAY, HONG KONG, Hong Kong, 999077. Work in the industry 2833 - (CF Office: Office of Life Sciences) MEDICINAL CHEMICALS & BOTANICAL PRODUCTS. Regencell Bioscience Holdings Ltd is a public company and trade via Over-The-Counter (OTC).Ownership
Updating!
Stock Chart
Coming soon!
Jobs
Coming soon!
Recent SEC Filings
Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Regencell Bioscience Holdings Ltd
| Filings | Format | Description | Filed/Effective | File/Film Number |
|---|---|---|---|---|
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-24-000003 (34 Act) Size: 45 KB |
Jan-02-2024 | 24500044 |
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-23-095864 (34 Act) Size: 20 KB |
Dec-15-2023 | 231488711 |
| 20-F | Document | Annual and transition report of foreign private issuers pursuant to sections 13 or 15(d) Acc-no: 0001013762-23-007289 (34 Act) Size: 5763 KB |
Oct-27-2023 | 231355708 |
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-23-049245 (34 Act) Size: 69 KB |
Jun-15-2023 | 231017277 |
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-23-045948 (34 Act) Size: 19 KB |
Jun-05-2023 | 23991135 |
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-23-020735 (34 Act) Size: 30 KB |
Mar-17-2023 | 23740607 |
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-23-015052 (34 Act) Size: 11 KB |
Feb-28-2023 | 23678908 |
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-23-000675 (34 Act) Size: 20 KB |
Jan-04-2023 | 23504385 |
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-22-081932 (34 Act) Size: 12 KB |
Dec-22-2022 | 221479705 |
| 20-F | Document | Annual and transition report of foreign private issuers pursuant to sections 13 or 15(d) Acc-no: 0001213900-22-067683 (34 Act) Size: 4926 KB |
Oct-31-2022 | 221346210 |
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-22-055210 (34 Act) Size: 54 KB |
Sep-12-2022 | 221237730 |
| SC 13D/A | Document | Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities Acc-no: 0001213900-22-041491 (34 Act) Size: 68 KB |
Jul-26-2022 | 221104973 |
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-22-030951 (34 Act) Size: 79 KB |
Jun-02-2022 | 22991010 |
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-22-027820 (34 Act) Size: 54 KB |
May-18-2022 | 22937099 |
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-22-026636 (34 Act) Size: 21 KB |
May-16-2022 | 22925293 |
| SC 13D/A | Document | Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities Acc-no: 0001213900-22-026630 (34 Act) Size: 61 KB |
May-16-2022 | 22925269 |
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-22-021532 (34 Act) Size: 11 KB |
Apr-26-2022 | 22851842 |
| SC 13D/A | Document | Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities Acc-no: 0001213900-22-017660 (34 Act) Size: 71 KB |
Apr-04-2022 | 22800376 |
| 6-K | Document | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments Acc-no: 0001213900-22-008083 (34 Act) Size: 57 KB |
Feb-16-2022 | 22643944 |
| SC 13D/A | Document | Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities Acc-no: 0001213900-21-068116 (34 Act) Size: 59 KB |
Dec-30-2021 | 211532893 |
Recent 20 filings. View all Regencell Bioscience Holdings Ltd filings
Reviews
Jean Bishop
Very good communication and delivery made within the timeframe I was advised of
Pelisari
young lad who new his job ansered questions and new what was best for me.
Samuel Ejimofor
It's being easier working on the website. And I recommend, it's a great website
Frequently Asked Questions
Tags:
- Regencell Bioscience Holdings Ltd overview
- Regencell Bioscience Holdings Ltd job
- Regencell Bioscience Holdings Ltd stock
- Regencell Bioscience Holdings Ltd ownership
- Regencell Bioscience Holdings Ltd CEO
- Regencell Bioscience Holdings Ltd documents
Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.
Orther Companies
Cordyceps Sunshine Biotech Holdings Co., Ltd.
Update: Jan 21, 2023
PSLY.COM, Inc.
Update: Aug 29, 2022
Jushi Holdings Inc.
Update: Aug 29, 2022
ZACHARY VENTURES INC
Update: Aug 25, 2022
WEIKANG BIO-TECHNOLOGY GROUP CO., INC.
Update: Aug 25, 2022
VITAQUEST INTERNATIONAL INC
Update: Aug 24, 2022
Latest News
SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate...
Charter Communications to Pay $25 Million Penalty for Unauthorized...
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries...
SEC Charges Royal Bank of Canada with Internal Accounting Controls...
SEC Charges President/CCO of Prophecy Asset Management Advisory...
SEC Adopts Rules for the Registration and Regulation of Security-Based...
SEC Charges Crypto Company SafeMoon and its Executive Team for...
© 2022 